WHO ICTRP trial
Clinical trial to assess the prognostic repercussions of rosuvastatin treatment…
EUCTR2020-001319-26-ES · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2020-001319-26-ES |
|---|---|
| Public title | Clinical trial to assess the prognostic repercussions of rosuvastatin treatment in patients discharged after hospitalization for COVID-19 Positive. |
| Scientific title | Multicenter, randomized, controlled, open-label clinical trial to assess the prognostic implications of rosuvastatin treatment in patients discharged after hospitalization for COVID-19 Positive. - FJD-COVID-ESTATINAS |
| Primary sponsor | Instituto de Investigación Sanitaria Fundación Jiménez Díaz |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | Spain |
| Conditions | COVID respiratory infection;Therapeutic area: Diseases [C] - Virus Diseases [C02] |
| Interventions | Pharmaceutical Form: Tablet INN or Proposed INN: ROSUVASTATIN CAS Number: 287714-41-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- |
| Registration date | May 14, 2020 |
| Target size | 1080 |
| Secondary IDs | FJD-COVID-ESTATINAS |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: